Beijing Slams 'Preemptive Prejudice' After ICMR Tells States to Stop Using Chinese Covid-19 Test Kits
File photo: Medics take samples for rapid test at Rajiv Gandhi Government General Hospital in Chennai. (PTI)
The statement comes after ICMR said it evaluated the kits of Guangzhou Wondfo Biotech and Zhuhai Livson Diagnostics in field conditions and found that results showed wide variation in their sensitivity.
- Last Updated: May 12, 2020, 08:38 IST
- FOLLOW US ON:
New Delhi: China on Tuesday expressed concern over Indian Council of Medical Research’s (ICMR) advisory to states asking them to stop using Covid-19 rapid antibody test kits procured from two Chinese companies.
“China attaches great importance to the quality of exported medical products. Recently, Chinese Embassy in India has maintained close contact with ICMR and the two Chinese companies to find out the real situation,” Chinese embassy spokesperson Ji Rong said in a statement on Tuesday.
The statement comes after ICMR sent an advisory to chief secretaries of all states and Union Territories on Monday. The ICMR said it "evaluated the kits of Guangzhou Wondfo Biotech and Zhuhai Livson Diagnostics in field conditions. The results have shown wide variation in their sensitivity, despite early promise of good performance for surveillance purpose".
The statement from the Chinese embassy spokesperson said that the two Chinese firms in question have already stressed that their antibody rapid test kits had obtained the certification from the National Medical Products Administration of China (NMPA) and have also been “validated and approved by ICMR through National Institute of Virology (NIV), Pune and considered as satisfactory products.”
Rong added that there are strict requirements for the storage, transportation and use of Covid-19 antibody rapid test kits and if any operation which is not carried out by professionals in accordance with the product specifications will lead to the “testing accuracy variations.”
Rong also said that it is “unfair and irresponsible for certain individuals” to label Chinese products as "faulty” and look at issues with "preemptive prejudice."
“...We hope the Indian side could respect China’s goodwill and sincerity, strengthen communication timely with relevant Chinese companies based on facts, and resolve it reasonably and properly.”
"We will continue to support India’s efforts in fighting Covid-19, strengthen medical and health cooperation, and jointly work with India to overcome the difficulties at an early date, so as to safeguard the safety and health of our peoples as well as global and regional public health security," Rong added.